Copy Link Print Information

Pemigatinib

(Synonyms: INCB054828)
22 Cited Publications
Avis client

Based on 22 publication(s) in Google Scholar

Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.84%
  • CAS No.: 1513857-77-6
  • Formule: C24H27F2N5O4
  • Masse moléculaire:487.50
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Pemigatinib Chemical Structure
    Pemigatinib Chemical Structure
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
  • Experimental Validation Results for Pemigatinib
CAS No.: 1513857-77-6
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Pemigatinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Pemigatinib

More
Customer Validation & Images
Cell Proliferation/Viability AssayIn Vivo ImagingWBRT-PCR2D/3D Cell Culture and Differentiation
  • Cell Proliferation/Viability Assay
  • In Vivo Imaging
  • WB
  • RT-PCR
  • 2D/3D Cell Culture and Differentiation
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
Keywords
100 mg

Obtenir un devis En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Pemigatinib Chemical Structure
    Pemigatinib Chemical Structure
    1/16
  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jun 24. [Abstract]

    Customer Validation
     Growth rate (GR)-corrected dose–response curves of NMuMG cells expressing indicated Fgfr2 variants and treated for 4 days with Pemigatinib (10-4-100 μM). Data are represented as mean ± SEM of n = 5 replicas per group.

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

    Customer Validation
     T07 cells (5 × 105) were injected into the tail vein of approximately 6-week-old female BALB/c mice, and after 3 days mice were randomized prior to dosing of Pemigatinib at (25 mg/kg; oral gavage). BLI of vehicle vs pemigatinib-treated mice on days 10 and 14. The results showed that Pemigatinib significantly reduced pulmonary tumor burden in these mice.

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

    Customer Validation
     4T07 cells were treated with Pemigatinib (Pemi, 10 nM) for the indicated amounts of time. Cells were lysed and analyzed by immunoblot for expression of PDGFR (α and β), ERK1/2 (phospho and total), and tubulin.

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

    Customer Validation
     4T07 cells were treated with Pemigatinib (10 nM) for 24 h and cells were analyzed by RT-PCR for expression of PDGFRa and PDGFRb.

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

    Customer Validation
     4T07 cells (2000 cells) were seeded under 3D culture conditions for 3 days at which point the cultures were left untreated (top row) or treated with Pemigatinib (50 nM; bottom row) for 96 h. Following drug treatment, cultures were allowed to recover in the absence or presence of PDGF-bb (100 ng/µL). Representative brightfield images are shown at the indicated days and treatment conditions.

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Aug;608(7923):609-617. [Abstract]

    Customer Validation
     Half-maximum inhibitory concentration (IC50) value quantifications of 2D-grown NMuMG cells expressing GFP or the indicated Fgfr2 variants and treated with AZD4547 or Pemigatinib for 4 days. Data are the mean of 5 independent experiments (GFP, Fgfr2FL, Fgfr2ΔE18) or 1 experiment (other Fgfr2 variants).

  • 1/16

    Pemigatinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Aug;608(7923):609-617. [Abstract]

    Customer Validation
     Dose-response curves of indicated human cancer cell lines treated with Pemigatinib (0.01-105 nM) for 4 days.

  • Pemigatinib